LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance

Rhea-AI Summary

LakeShore Biopharma (Nasdaq: LSB) has provided financial guidance for the first half of fiscal year 2025 and reaffirmed its full-year guidance, highlighting strong execution and positive business momentum. The company anticipates double-digit year-over-year revenue growth for FY2025 and expects to achieve breakeven during this period. Preliminary total revenue for the first six months is estimated between RMB350 million to RMB380 million, representing a 28% to 39% growth from the same period in FY2024.

LakeShore Biopharma is pursuing strategic initiatives including cost reductions, organizational restructuring, and management process enhancements to boost operational efficiency. The company is also focused on driving future growth through strategic alliances, product licensing, asset purchases, partnerships, and co-promotion deals. CEO Xu Wang expressed confidence in maintaining positive momentum and achieving financial and operational objectives, noting the company's second position in China's Rabies vaccine market and its commitment to enhancing sustainability, efficiency, and innovation.

Positive

• Anticipated double-digit year-over-year revenue growth for FY2025
• Estimated 28% to 39% revenue growth for the first six months of FY2025
• Expected to achieve breakeven during FY2025
• Secured second position in China's Rabies vaccine market
• Pursuing strategic initiatives to boost operational efficiency and reduce costs
• Driving future growth through strategic alliances and partnerships

Negative

• None.

News Market Reaction – LSB

+21.15%

1 alert

+21.15% News Effect

On the day this news was published, LSB gained 21.15%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

GAITHERSBURG, Md., Oct. 8, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it is providing financial guidance for the half year of its fiscal year of 2025 and reaffirming its financial guidance for the full year of its fiscal year 2025 ending on March 31, 2025 ("Fiscal Year 2025"), underlining the Company's strong execution and positive business momentum.

LakeShore Biopharma's previously issued guidance anticipated double-digit year-over-year revenue growth during Fiscal Year 2025 and noted that the Company expected to achieve breakeven during the period. The Company's performance in the first six months of its Fiscal Year 2025 has demonstrated solid progress towards these goals, with a preliminary total revenue estimate for the first six months in the range of RMB350 million to RMB380 million, representing substantial growth of 28% to 39% from RMB273.1 million in revenues during the same period in its fiscal year 2024.

In addition to advancing its existing pipeline, LakeShore Biopharma has been vigorously pursuing strategic initiatives including cost reductions, organizational restructuring and optimization, and management process enhancements to boost operational efficiency and eliminate non-essential expenditures. Furthermore, the Company is also committed to driving future growth through strategic alliances, including product licensing, asset purchase agreements, partnerships, and co-promotion deals with more diversified pipeline products.

Mr. Xu Wang, Chief Executive Officer of the Company, commented, "By reaffirming our full-year guidance, we are expressing belief in our ability to maintain our positive momentum and achieve our financial and operational objectives. With our new management team in place, Lakeshore Biopharma has not only maintained smooth operations, but also secured second position in China's Rabies vaccine market. Armed with a robust business model and a strong pipeline, we have consistently demonstrated our capacity to execute our core strategies effectively. Building on this solid foundation, we are actively forging long-term strategic partnerships through licensing, promotions, and other collaborative agreements. As we progress through Fiscal Year 2025 with a clear plan to enhance sustainability, efficiency, and innovation, I am confident that our team will deliver success across these areas, creating enduring value for our company and our shareholders."

About LakeShore Biopharma
LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The Company operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.lakeshorebio.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth of LakeShore Biopharma, the development progress of all product candidates, the progress and results of all clinical trials, LakeShore Biopharma's ability to source and retain talent, and the cash position of LakeShore Biopharma. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "potential," "forecast," "intend," "will," "expect," "anticipate," "believe," "goal," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether identified in this press release, and on the current expectations of LakeShore Biopharma's management and are not predictions of actual performance.

LakeShore Biopharma cannot assure you the forward-looking statements in this press release will be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including those included under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission (the "SEC"), and other risks described in documents subsequently filed or furnished by the Company from time to time with the SEC. There may be additional risks that LakeShore Biopharma does not presently know or that LakeShore Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of LakeShore Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while LakeShore Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of LakeShore Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, LakeShore Biopharma does not undertake any duty to update these forward-looking statements.

Investor Relations Contact
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: LakeShoreBiopharma.IR@icrinc.com

 

View original content:https://www.prnewswire.com/news-releases/lakeshore-biopharma-provides-fiscal-half-year-2025-financial-guidance-and-reaffirms-fiscal-year-2025-financial-guidance-302270029.html

SOURCE LakeShore Biopharma Co., Ltd.

FAQ

What is LakeShore Biopharma's revenue guidance for the first half of fiscal year 2025?

LakeShore Biopharma estimates preliminary total revenue for the first six months of fiscal year 2025 to be between RMB350 million to RMB380 million, representing a 28% to 39% growth from the same period in fiscal year 2024.

Has LakeShore Biopharma (LSB) reaffirmed its full-year guidance for fiscal year 2025?

Yes, LakeShore Biopharma has reaffirmed its financial guidance for the full fiscal year 2025, anticipating double-digit year-over-year revenue growth and expecting to achieve breakeven during this period.

What strategic initiatives is LakeShore Biopharma (LSB) pursuing to boost operational efficiency?

LakeShore Biopharma is pursuing cost reductions, organizational restructuring, management process enhancements, and strategic alliances including product licensing, asset purchases, partnerships, and co-promotion deals to boost operational efficiency and drive future growth.

What is LakeShore Biopharma's (LSB) position in China's Rabies vaccine market as of October 2024?

According to the press release, LakeShore Biopharma has secured the second position in China's Rabies vaccine market.